Profile data is unavailable for this security.
About the company
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.
- Revenue in USD (TTM)40.56m
- Net income in USD-218.90m
- Incorporated2017
- Employees168.00
- LocationZentalis Pharmaceuticals Inc1359 Broadway, Suite 801NEW YORK 10018United StatesUSA
- Phone+1 (212) 433-3791
- Fax+1 (302) 655-5049
- Websitehttps://www.zentalis.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ProKidney Corp | 0.00 | -35.30m | 806.31m | 163.00 | -- | -- | -- | -- | -0.567 | -0.567 | 0.00 | -17.79 | 0.00 | -- | -- | 0.00 | -30.32 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | 67.17 | -- | -- | -- |
Evolus Inc | 219.70m | -60.00m | 809.55m | 279.00 | -- | 43.66 | -- | 3.68 | -1.05 | -1.05 | 3.82 | 0.2962 | 1.14 | 3.86 | 7.62 | 804,750.90 | -31.06 | -40.92 | -40.14 | -59.74 | 69.28 | 65.43 | -27.31 | -80.46 | 2.96 | -2.90 | 0.8674 | -- | 35.98 | -- | 17.10 | -- | 182.77 | -- |
Praxis Precision Medicines Inc | 2.20m | -125.38m | 811.94m | 82.00 | -- | 2.74 | -- | 369.90 | -15.91 | -15.91 | 0.2394 | 17.32 | 0.0126 | -- | -- | 26,768.29 | -71.89 | -74.04 | -83.56 | -85.12 | -- | -- | -5,711.85 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
Disc Medicine Inc | 0.00 | -80.60m | 839.29m | 74.00 | -- | 2.48 | -- | -- | -3.37 | -3.37 | 0.00 | 13.69 | 0.00 | -- | -- | 0.00 | -26.96 | -- | -28.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
Zentalis Pharmaceuticals Inc | 40.56m | -218.90m | 843.64m | 168.00 | -- | 1.84 | -- | 20.80 | -3.36 | -3.36 | 0.5934 | 6.46 | 0.0775 | -- | 7.09 | 241,428.60 | -39.22 | -47.40 | -43.89 | -54.18 | -- | -- | -506.16 | -- | -- | -- | 0.00 | -- | -- | -- | -23.39 | -- | 20.76 | -- |
Relay Therapeutics Inc | 35.33m | -329.12m | 850.87m | 309.00 | -- | 1.14 | -- | 24.09 | -2.64 | -2.64 | 0.2841 | 5.64 | 0.0376 | -- | -- | 109,371.50 | -35.03 | -28.55 | -37.16 | -29.54 | -- | -- | -931.64 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
Tyra Biosciences Inc | 0.00 | -75.45m | 852.20m | 49.00 | -- | 2.18 | -- | -- | -1.68 | -1.68 | 0.00 | 7.43 | 0.00 | -- | -- | 0.00 | -22.87 | -- | -23.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
ARS Pharmaceuticals Inc | 10.00k | -49.70m | 860.43m | 24.00 | -- | 3.83 | -- | 86,042.98 | -0.5198 | -0.5198 | 0.0001 | 2.32 | 0.00004 | -- | -- | 416.67 | -19.93 | -20.37 | -20.48 | -21.32 | -- | -- | -496,960.00 | -17,491.75 | -- | -- | 0.00 | -- | -97.72 | -- | -56.75 | -- | -17.18 | -- |
Perspective Therapeutics Inc | -304.00k | -48.91m | 881.04m | 116.00 | -- | 3.52 | -- | -- | -0.1622 | -0.197 | -0.0009 | 0.3917 | -0.0015 | -- | -- | -2,620.69 | -24.10 | -- | -25.46 | -- | -- | -- | -- | -- | -- | -- | 0.0074 | -- | -- | -- | -- | -- | -- | -- |
Ocular Therapeutix Inc | 59.84m | -115.27m | 882.87m | 267.00 | -- | 2.16 | -- | 14.75 | -1.09 | -1.09 | 0.6335 | 2.64 | 0.1793 | 2.23 | 2.51 | 224,127.30 | -34.54 | -46.70 | -37.58 | -54.18 | 90.99 | 89.36 | -192.62 | -228.65 | 21.29 | -9.10 | 0.1401 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
Humacyte Inc | 0.00 | -105.70m | 890.75m | 183.00 | -- | 34.06 | -- | -- | -1.01 | -1.01 | 0.00 | 0.2196 | 0.00 | -- | -- | 0.00 | -61.38 | -- | -68.92 | -- | -- | -- | -- | -- | -- | -61.50 | 0.4145 | -- | -100.00 | -- | -825.83 | -- | -- | -- |
Immunome Inc | 12.68m | -232.03m | 895.93m | 55.00 | -- | 3.12 | -- | 70.64 | -5.49 | -5.49 | 0.4273 | 4.78 | 0.069 | -- | -- | 230,600.00 | -126.15 | -94.54 | -148.61 | -112.66 | -- | -- | -1,829.44 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
USANA Health Sciences, Inc. | 900.45m | 61.94m | 906.81m | 1.80k | 14.86 | 1.81 | 12.17 | 1.01 | 3.20 | 3.20 | 46.56 | 26.25 | 1.46 | 2.73 | -- | 500,250.00 | 10.03 | 16.23 | 12.49 | 21.75 | 80.98 | 81.42 | 6.88 | 8.96 | 3.20 | -- | 0.0026 | 0.00 | -7.77 | -4.98 | -8.02 | -12.76 | 4.86 | -- |
Holder | Shares | % Held |
---|---|---|
Matrix Capital Management Co. LPas of 31 Mar 2024 | 13.96m | 19.67% |
Eventide Asset Management LLCas of 31 Mar 2024 | 11.57m | 16.31% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 9.61m | 13.55% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 4.24m | 5.98% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 4.23m | 5.96% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 3.79m | 5.34% |
Citadel Advisors LLCas of 31 Mar 2024 | 3.61m | 5.09% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 3.43m | 4.84% |
T. Rowe Price Investment Management, Inc.as of 31 Mar 2024 | 3.32m | 4.68% |
Capital Research & Management Co. (International Investors)as of 31 Mar 2024 | 2.82m | 3.97% |